<DOC>
	<DOCNO>NCT01167322</DOCNO>
	<brief_summary>The aim present Phase III study assess positive predictive value NPC-07 ( 5-aminolevulinic acid hydrochloride ) induce tissue fluorescence , safety pharmacokinetics follow single dose NPC-07 orally , dose 20mg/kg/body weight , 3 hour prior induction anaesthesia surgery patient newly recurrent malignant glioma ( WHO grade III/IV ) . Positive predictive value confirm percentage patient show positive tumor cell identification biopsy take area strong weak fluorescence . This study divide two stage . After review result safety pharmacokinetics NPC-07 small number subject independent safety monitoring committee , subject receive NPC-07 Step II .</brief_summary>
	<brief_title>Study NPC-07 Fluorescence-guided Resection Malignant Gliomas</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<criteria>Aged 18 70 year . Radiological suspicion newly recurrent malignant glioma ( WHO grade III/IV ) . Indication surgical tumor resection . Karnofsky Performance Score 60 high . Provides sign informed consent prior study procedure . Comply visit schedule rule patient study protocol . Porphyria , hypersensitivity porphyrin . Renal insufficiency : Creatinine 2.0 mg/dL high Hepatic insufficiency : ALT 100 IU/L high , AST 100 IU/L high , Î³GTP 100 IU/L high total bilirubin 3 mg/dL high Chemotherapy treatment malignant tumor Females pregnant potentially childbearing breastfeed Participation clinical trial previous 1 month Ineligible patient base judgement investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>NPC-07 , 5-ALA , photodynamic diagnosis , pharmacokinetics</keyword>
</DOC>